DK0589840T3 - Omdannede monoklonale antistoffer mod en immunoglobulinisotype - Google Patents

Omdannede monoklonale antistoffer mod en immunoglobulinisotype

Info

Publication number
DK0589840T3
DK0589840T3 DK93810653T DK93810653T DK0589840T3 DK 0589840 T3 DK0589840 T3 DK 0589840T3 DK 93810653 T DK93810653 T DK 93810653T DK 93810653 T DK93810653 T DK 93810653T DK 0589840 T3 DK0589840 T3 DK 0589840T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
converted
immunoglobulin isotype
immunoglobulin
isotype
Prior art date
Application number
DK93810653T
Other languages
English (en)
Inventor
Jose Saldanha
Norman Hardman
Frank Kolbinger
Original Assignee
Novartis Ag
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220228A external-priority patent/GB9220228D0/en
Application filed by Novartis Ag, Tanox Inc filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0589840T3 publication Critical patent/DK0589840T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
DK93810653T 1992-09-24 1993-09-15 Omdannede monoklonale antistoffer mod en immunoglobulinisotype DK0589840T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929220228A GB9220228D0 (en) 1992-09-24 1992-09-24 Reshaped monoclonal antibodies against an immunologlobulin isotype
US95280292A 1992-09-25 1992-09-25

Publications (1)

Publication Number Publication Date
DK0589840T3 true DK0589840T3 (da) 2004-07-26

Family

ID=26301683

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93810653T DK0589840T3 (da) 1992-09-24 1993-09-15 Omdannede monoklonale antistoffer mod en immunoglobulinisotype

Country Status (18)

Country Link
EP (2) EP0589840B1 (da)
JP (2) JP3636737B2 (da)
KR (1) KR100298608B1 (da)
CN (2) CN1078250C (da)
AT (1) ATE264388T1 (da)
AU (1) AU675449B2 (da)
CA (1) CA2106719C (da)
CY (1) CY2583B2 (da)
DE (1) DE69333484T2 (da)
DK (1) DK0589840T3 (da)
ES (1) ES2219640T3 (da)
FI (2) FI114550B (da)
HK (1) HK1056182A1 (da)
IL (2) IL107049A (da)
MX (1) MX9305920A (da)
NO (1) NO318210B1 (da)
NZ (1) NZ248743A (da)
PT (1) PT589840E (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
AU7156996A (en) * 1995-09-13 1997-04-01 Genentech Inc. Methods for treatment of interstitial cystitis
US6127524A (en) * 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
EP1056471A4 (en) * 1998-01-29 2001-05-30 Tanox Inc TREATMENT OF ATOPIC DERMATITIS USING IgE ANTAGONISTS
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP2316852B1 (en) 2002-11-08 2014-03-05 Ablynx N.V. Stabilized single domain antibodies
EP1558646A2 (en) * 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
EP2000481B1 (en) * 2003-02-01 2016-03-30 Tanox, Inc. High affinity anti-human IgE antibodies
KR20070008578A (ko) * 2004-02-02 2007-01-17 타녹스 인코퍼레이티드 신규한 ＩｇＥ 에피토프의 확인
KR101581986B1 (ko) 2008-10-29 2016-01-04 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
CN102272154A (zh) 2008-10-29 2011-12-07 惠氏有限责任公司 单域抗原结合性分子的纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2724625B2 (ja) * 1987-12-31 1998-03-09 タノックス・バイオシステムズ・インコーポレーテッド ＩｇＥ産出性Ｂリンパ球上の独特な抗原決定基
US5104604A (en) * 1989-10-05 1992-04-14 Dexter Electronic Materials Div. Of Dexter Corp. Flame retardant epoxy molding compound, method and encapsulated device method of encapsulating a semiconductor device with a flame retardant epoxy molding compound
JP2988635B2 (ja) * 1990-09-18 1999-12-13 塩野義製薬株式会社 ヒトＩｇＥに対するモノクローナル抗体
WO1992017207A1 (en) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
ATE233813T1 (de) * 1991-08-14 2003-03-15 Genentech Inc Veränderte immunglobuline für spezifische fc- epsilon rezeptoren

Also Published As

Publication number Publication date
CN1088986A (zh) 1994-07-06
KR100298608B1 (ko) 2001-11-22
CN1078250C (zh) 2002-01-23
CA2106719A1 (en) 1994-03-25
JP2004357712A (ja) 2004-12-24
NZ248743A (en) 1995-04-27
ATE264388T1 (de) 2004-04-15
CN1428352A (zh) 2003-07-09
FI934145A0 (fi) 1993-09-22
EP0589840B1 (en) 2004-04-14
HK1056182A1 (en) 2004-02-06
FI934145A (fi) 1994-03-25
CA2106719C (en) 2006-03-28
FI114550B (fi) 2004-11-15
FI115838B (fi) 2005-07-29
NO933394D0 (no) 1993-09-23
MX9305920A (es) 1994-05-31
EP1452542A3 (en) 2007-05-02
NO933394L (no) 1994-03-25
AU675449B2 (en) 1997-02-06
IL173988A0 (en) 2006-07-05
NO318210B1 (no) 2005-02-21
EP0589840A1 (en) 1994-03-30
DE69333484T2 (de) 2005-03-24
CN1254487C (zh) 2006-05-03
JP3718214B2 (ja) 2005-11-24
EP1452542A2 (en) 2004-09-01
FI20040696A (fi) 2004-05-19
IL107049A (en) 2006-07-05
CY2583B2 (en) 2009-11-04
JP3636737B2 (ja) 2005-04-06
PT589840E (pt) 2004-08-31
IL107049A0 (en) 1993-12-28
AU4748893A (en) 1994-03-31
ES2219640T3 (es) 2004-12-01
DE69333484D1 (de) 2004-05-19
KR940006602A (ko) 1994-04-25
JPH06225788A (ja) 1994-08-16

Similar Documents

Publication Publication Date Title
CY2583B2 (en) Reshaped monoclonal antibodies against an immunoglobulin isotype
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DK0758904T3 (da) Fremgangsmåder og sammensætninger til behandling af glomerulonephritis
NO2017040I2 (no) Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
ES2116298T3 (es) Nuevo metodo de tratamiento de la depresion.
ATE151078T1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
DE69029858T2 (de) Behandlung von einer autoimmun-krankheit
RU93035807A (ru) Способ лечения юношеского эпифизиолиса